Which stock wins in a matchup between these two healthcare siblings?
News & Analysis: AbbVie
What does the future hold for this well-regarded Dividend Aristocrat?
AbbVie's shares had an off year in 2019. Here's why.
The big drugmaker's top executives laid out a vision for AbbVie's future at the J.P. Morgan Healthcare Conference this week.
The results should help the upstart drug to compete with Cosentyx.
The stock has already rallied 20% over the past three months, and with a new drug in the mix, it could continue to climb even higher.
All your Motley Fool coverage of the 2020 J.P. Morgan Healthcare Conference in one place.
A big drugmaker, a global utility company, and an intriguing REIT top my list of great dividend stocks to buy.
The company is leaving the aesthetics unit largely intact.
Both of these pharma giants have encountered obstacles recently, but which of them is the better buy now?